NABI » Topics » RECONCILIATION OF REVENUE:

This excerpt taken from the NABI 8-K filed Oct 25, 2006.

RECONCILIATION OF REVENUE:

 

     For the Three Months Ended
     September 30,
2006
   September 24,
2005

Revenue from Continuing Operations

     

Biopharmaceutical Products

   $ 7,424    $ 11,821

Antibody Products:

     

Specialty antibodies

     6,257      4,143

Non-specific antibodies

     5,953      6,410
             

Total antibodies

     12,210      10,553
             

Total revenue from Continuing Operations

     19,634      22,374

Revenue from Discontinued Operations

     6,789      8,117
             

Total revenue

   $ 26,423    $ 30,491
             

XXX

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki